NetworkNewsBreaks – Delic Holdings Corp. (CSE: D
Post# of 135
(Total Views: 196)
Posted On: 04/13/2022 3:39:19 PM
NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Health Canada 56 Exemption for Research on Psychedelic Compounds
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its subsidiary Delic Labs have received a Health Canada 56 Research Exemption. The exemption gives approval for the company to conduct research and perform tests on several compounds, including MDMA, LSD, mescaline and 2C-B. The exemption also allows the lab to obtain psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. The company anticipates moving forward and developing innovative analytical methods for psychedelic research. According to the announcement, the lab has also submitted an application for a dealer’s license with the intent of commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes. “Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds,” said Delic Labs cofounder Dr. Markus Roggen in the press release. “Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercializing the research once our dealer’s license is secured.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its subsidiary Delic Labs have received a Health Canada 56 Research Exemption. The exemption gives approval for the company to conduct research and perform tests on several compounds, including MDMA, LSD, mescaline and 2C-B. The exemption also allows the lab to obtain psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. The company anticipates moving forward and developing innovative analytical methods for psychedelic research. According to the announcement, the lab has also submitted an application for a dealer’s license with the intent of commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes. “Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds,” said Delic Labs cofounder Dr. Markus Roggen in the press release. “Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercializing the research once our dealer’s license is secured.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Delic Holdings Corp (DELCF) Stock Research Links
Scroll down for more posts ▼